Clinical Pharmacogenetics Implementation Consortium
ClinPGx Logo

ClinPGx 2024: Knowledge, Implementation, Education Meeting
June 20th and 21st, 2024 in Philadelphia, PA

More information

What is CPIC?

The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium of individual volunteers and a small dedicated staff who are interested in facilitating use of pharmacogenetic tests for patient care.

One barrier to implementation of pharmacogenetic testing in the clinic is the difficulty in translating genetic laboratory test results into actionable prescribing decisions for affected drugs.

CPIC’s goal is to address this barrier to clinical implementation of pharmacogenetic tests by creating, curating, and posting freely available, peer-reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines (click here for all CPIC publications).  CPIC guidelines follow standardized formats, include systematic grading of evidence and clinical recommendations, use standardized terminology, are peer-reviewed, and are published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to cpicpgx.org, where they are regularly updated.

CPIC started as a shared project between PharmGKB and the Pharmacogenomics Research Network (PGRN) in 2009. CPIC guidelines are indexed in PubMed as clinical guidelines, endorsed by ASHP and ASCPT, and referenced in ClinGen and PharmGKB.

Additionally, the College of American Pathologists (CAP)  has stated: “CAP applauds and supports the objectives, processes and work completed as of December 2018 by the Clinical Pharmacogenetics Implementation Consortium (CPIC®). These efforts will help clinicians, laboratories, health care providers and vendors.”

CPIC resources are freely available under a Creative Commons public domain license.
Read the license page for more details.

Team

CPIC Co-Principal Investigators
Kelly E. Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital

Teri E. Klein, Ph.D.
Stanford University

Co-Investigator

Michelle Whirl-Carrillo, Ph.D.
Stanford University

Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital

James M. Hoffman, Pharm.D.
St. Jude Children’s Research Hospital

Steering Committee

Teri E. Klein, Ph.D.
Stanford University

Kelly E. Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital

Michelle Whirl-Carrillo, Ph.D.
Stanford University

Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital

Dan M. Roden, M.D.
Vanderbilt University

Rachel F. Tyndale, Ph.D.
University of Toronto and CAMH

Larisa Cavallari, Pharm.D.
University of Florida

Stuart A. Scott, Ph.D.
Stanford University and Stanford Healthcare

Sara Van Driest, M.D., Ph.D.
Vanderbilt University

News & Announcements

  • Data from PharmGKB clinical annotations are now integrated into OpenTargets; a free online tool which brings together data from publicly available datasets to help prioritize potential drug targets.The Pharmacogenetics section of the profile for both drugs and targets (genes) now shows information from PharmGKB clinical annotations, including the phenotype category and the Level of Evidence. By hovering over […]
  • CPIC has updated guidance for patients who are both TPMT and NUDT15 Intermediate Metabolizers from "Clinical Pharmacogenetics Implementation Consortium Guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update". From the CPIC website:"At the time of guideline publication, the extent of reduction for thiopurines recommended for patients with intermediate metabolism for both TPMT and […]
  • Pharmacogenomics Clinical Annotation Tool (PharmCAT) tutorial videos are now available on the PharmGKB YouTube channel. The tutorial videos provide clear, step-by-step instructions for running PharmCAT from command lines. By providing genotype-based drug prescribing recommendations, we hope to engage the wider genomics community and create a standard for the use in precision medicine. The first two […]
  • PharmVar and PharmGKB are excited to share that NAT2 has been transitioned into the PharmVar database and updated accordingly on PharmGKB. NAT2 metabolizes several pharmaceutical substrates, including isoniazid, hydralazine, amifampridine, procainamide and sulfonamides, as well as some highly carcinogenic arylamines. NAT2 enzymatic activity varies considerably between individuals, due to polymorphisms in NAT2 coding sequence that may be found more […]
  •  REGISTRATION OPENIn collaboration with CPIC, PharmGKB, PharmCAT and PharmVar, the Penn Institute for Biomedical Informatics will be hosting the ClinPGx 2024: Knowledge, Implementation, Education meeting on June 20th and 21st, 2024 in Philadelphia, PA. This meeting will provide educational content to cover all aspects of PGx implementation, including knowledgebases, implementation strategy, informatics, use of AI in precision […]

Follow @cpicpgx on Twitter